Evidence map›Paper›PMID 30034127›Full record

ReviewIndian journal of urology : IJU : journal of the Urological Society of India

STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs.

Aditya Prakash Sharma, Ravimohan S Mavuduru, Girdhar Singh Bora, Sudheer K Devana, Shrawan K Singh, Arup K Mandal

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Indian journal of urology : IJU : journal of the Urological Society of India. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. What's inside?Indian journal of urology : IJU : journal of the Urological Society of India
    Article
  5. Article
  6. Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer.Indian journal of urology : IJU : journal of the Urological Society of India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aditya Prakash SharmaDepartment of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Ravimohan S MavuduruDepartment of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Girdhar Singh BoraDepartment of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Sudheer K DevanaDepartment of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Shrawan K SinghDepartment of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Arup K MandalDepartment of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the emergence of recent landmark trials, the treatment for hormone-sensitive metastatic prostate cancer (hsMPC) is changing from androgen deprivation therapy (ADT) alone to combination therapy. Both, docetaxel chemotherapy and abiraterone in addition to ADT have been extensively studied in well-conducted randomized controlled trials and were shown to improve outcomes. However, this paradigm shift in the treatment has also raised some queries. This mini review reflects upon the four landmark trials and tries to provide some perspective about the decision-making process for the patients with hsMPC.

Identifiers

PMID30034127
PMCPMC6034411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.